Physician profile
James Wesley Hall
NPI 1295735504
$7,040.02
in general payments reported to CMS, 2019-2025
43 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $466 · 2021: $1,171 · 2022: $1,199 · 2023: $1,258 · 2024: $1,566 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,414.21 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,091.47 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $744.92 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $696.00 | 2022-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Abbvie INC. | $564.08 | 2021-2025 | |
| Novo Nordisk INC | $551.14 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $460.09 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $313.72 | 2019-2022 | |
| Astellas Pharma US INC | $256.65 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $252.85 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.24 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $214.12 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $141.04 | 2019-2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $118.46 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $106.28 | 2019-2024 | Trintellix |
| Antares Pharma, INC. | $97.31 | 2023-2025 | Xyosted, Nocdurna, Tlando |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.